Product Description: Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively. Mavorixafor can be used for the study of WHIM syndrome[1].
Applications: COVID-19-anti-virus
Formula: C21H27N5
Citations: Biosci Rep. 2023 Dec 22;43(12):BSR20230981./Br J Haematol. 2022 Dec 19./Cell Mol Life Sci. 2024 Mar 13;81(1):132./Patent. US20220273751A1./PLoS One. 2016 Mar 21;11(3):e0151765./Am J Physiol Cell Physiol. 2025 Mar 10./Oncol Rep. 2022 Apr;47(4):68./Proc Natl Acad Sci U S A. 2025 Mar 18;122(11):e2425795122.
References: [1]Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88./[2]Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308.
CAS Number: 558447-26-0
Molecular Weight: 349.47
Compound Purity: 95.0
Research Area: Infection; Endocrinology; Cancer
Solubility: 10 mM in DMSO
Target: CXCR;HIV
Deutsch
English
